Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Ryvu Therapeutics S.A. (WSE: RVU)

Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology. Pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, immuno-oncology and cancer metabolism targets. SEL120 is a selective CDK8 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome. SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia. Ryvu is listed on the Warsaw Stock Exchange in Poland (WSE:RVU). *

 

Period Start 2020-04-16 splitoff before
  Predecessor Selvita S.A. (WSE:SLV)
Products Industry drug discovery
  Industry 2 small-molecule drug
Person Person Przewiezlikowski, Pawel (Selvita 201309 CEO + Co-Founder)
     
Region Region Kraków
  Country Poland
  City n. a. Kraków
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Galapagos N.V.. (4/16/20). "Press Release: Galapagos and Ryvu Announce Research Collaboration". Mechelen & Krakow.
     
   
Record changed: 2021-03-22

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Ryvu Therapeutics S.A. (WSE: RVU)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80




» top